Exelixis
EXEL
#1799
Rank
โ‚น1.036 T
Marketcap
โ‚น3,865
Share price
0.02%
Change (1 day)
20.41%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น205.34

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น222.89. In 2023 the company made an earnings per share (EPS) of โ‚น61.18 an increase over its 2022 EPS that were of โ‚น53.38.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น205.34
2023โ‚น61.1814.61%
2022โ‚น53.38-22.97%
2021โ‚น69.30100%
2020โ‚น34.65-65.09%
2019โ‚น99.27-53.91%
2018โ‚น215.40333.96%
2017โ‚น49.64-260.61%
2016-โ‚น30.91-58.75%
2015-โ‚น74.92-42.45%
2014-โ‚น130.185.3%
2013-โ‚น123.62

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น1,043 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น127.37-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,342 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น193.41-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น684.29 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น278.15 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น352.88 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น343.70-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น78.67-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA